Tolleson Wealth Management Inc. Makes New Investment in Johnson & Johnson (NYSE:JNJ)

Tolleson Wealth Management Inc. purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,677 shares of the company's stock, valued at approximately $243,000.

A number of other large investors have also bought and sold shares of the stock. Trace Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $576,000. True Wealth Design LLC grew its holdings in Johnson & Johnson by 52.9% in the fourth quarter. True Wealth Design LLC now owns 1,225 shares of the company's stock worth $177,000 after purchasing an additional 424 shares during the period. State of Wyoming grew its holdings in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares during the period. Strive Asset Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $650,000. Finally, Tang Capital Management LLC grew its holdings in Johnson & Johnson by 58.7% in the fourth quarter. Tang Capital Management LLC now owns 7,959 shares of the company's stock worth $1,151,000 after purchasing an additional 2,944 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 1.2%

Johnson & Johnson stock opened at $151.37 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market cap of $364.20 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The firm's 50-day simple moving average is $156.27 and its 200 day simple moving average is $153.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.44%. Johnson & Johnson's payout ratio is currently 57.84%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.